DE
DefZone.Net

Kien thuc cong nghe & giai tri

Wiki Article

Camizestrant

Nguồn dữ liệu từ Wikipedia, hiển thị bởi DefZone.Net

Xem trên WikipediaBài ngẫu nhiên khác

Camizestrant
Clinical data
Pronunciation/ˌkæmɪˈzɛstrənt/
KAM-ih-ZES-trənt
Trade namesEtcamah
Other namesAZD9833
AHFS/Drugs.comEtcamah
License data
Routes of
administration		By mouth
Drug classAntineoplastic
ATC code
Legal status
Legal status
Identifiers
  • N-[1-(3-fluoropropyl)azetidin-3-yl]-6-[(6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-3,6,8,9-tetrahydropyrazolo[4,3-f]isoquinolin-6-yl]pyridin-3-amine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC24H28F4N6
Molar mass476.524 g·mol−1
3D model (JSmol)
  • C[C@@H]1CC2=C(C=CC3=C2C=NN3)[C@H](N1CC(F)(F)F)C4=NC=C(C=C4)NC5CN(C5)CCCF
  • InChI=1S/C24H28F4N6/c1-15-9-19-18(4-6-21-20(19)11-30-32-21)23(34(15)14-24(26,27)28)22-5-3-16(10-29-22)31-17-12-33(13-17)8-2-7-25/h3-6,10-11,15,17,23,31H,2,7-9,12-14H2,1H3,(H,30,32)/t15-,23+/m1/s1
  • Key:WDHOIABIERMLGY-CMJOXMDJSA-N

Camizestrant, sold under the brand name Etcamah, is an anti-cancer medication used for the treatment of breast cancer.[3] It is an estrogen receptor alpha antagonist and a selective estrogen receptor degrader (SERD).[5]

Camizestrant is an oral selective estrogen receptor degrader (ngSERD) and complete estrogen receptor (ER) antagonist.[3] It blocks the activity of estrogen receptor alpha encoded by both wild-type and mutated ESR1 and induces proteasome-dependent degradation of estrogen receptor alpha, without agonizing estrogen receptor alpha.[3]

Camizestrant was authorized for medical use in the European Union in July 2026,[3] and in the United States in September 2026.[2][6]

Medical uses

[edit]

Camizestrant in combination with a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) is indicated for the treatment of adults with ER-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of ESR1‑mutation and without disease progression during first-line endocrine therapy in combination with a CDK4/6 inhibitor.[3]

Side effects

[edit]

The U.S. prescribing information includes a boxed warning for the risk of irregular heart rhythm when camizestrant is taken together with certain other medications, as well as warnings and precautions for an abnormally slow heart rate and potential harm to an unborn baby.[6]

Society and culture

[edit]
[edit]

In June 2026, the United Arab Emirates was the first country to approve camizestrant.[7]

In May 2026, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Etcamah, intended for the treatment of ER-positive, HER2-negative locally advanced or metastatic breast cancer in people with ESR1 gene mutations.[3] The applicant for this medicinal product is AstraZeneca AB.[3] Camizestrant was authorized for medical use in the European Union in July 2026.[4]

Names

[edit]

Camizestrant is the international nonproprietary name.[8]

Camizestrant is sold under the brand name Etcamah.[3]

References

[edit]
  1. ^ "Register of Innovative Drugs". Health Canada. 24 September 2026. Retrieved 5 October 2026.
  2. ^ a b "FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer". U.S. Food and Drug Administration FDA. 4 September 2026. Retrieved 4 September 2026.
  3. ^ a b c d e f g h i "Etcamah EPAR". European Medicines Agency (EMA). 22 May 2026. Retrieved 30 May 2026. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  4. ^ a b "Etcamah PI". Union Register of medicinal products. 22 July 2026. Retrieved 8 September 2026.
  5. ^ Scott JS, Moss TA, Balazs A, Barlaam B, Breed J, Carbajo RJ, et al. (December 2020). "Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist". Journal of Medicinal Chemistry. 63 (23): 14530–14559. doi:10.1021/acs.jmedchem.0c01163. PMID 32910656.
  6. ^ a b "FDA Grants Accelerated Approval to a New Breast Cancer Treatment" (Press release). U.S. Food and Drug Administration FDA. 4 September 2026. Retrieved 8 September 2026.
  7. ^ Saseendran S (11 June 2026). "UAE first country in world to approve new oral breast cancer drug for hormone-resistant cases".
  8. ^ World Health Organization (2022). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 87". WHO Drug Information. 36 (1). hdl:10665/352794.
[edit]